ReviewExploration (Beijing, China)2024
Recent advances in bacteria-based platforms for inflammatory bowel diseases treatment.
Review in Exploration (Beijing, China), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Comparative Effectiveness and Safety of Fecal Microbiota Transplantation in Ulcerative Colitis: An Updated Systematic Review and Meta-Analysis.Advances in therapy · 2026Pooled it
- Uhrf1-Mediated PKM2 Degradation via Ubiquitination Alleviates Inflammation and Pyroptosis in Inflammatory Bowel Disease.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Polysaccharide-Based Encapsulation of Microbes for Enhanced Microbial Therapy.Polymer science & technology (Washington, D.C.) · 2026Review
- From dysbacteriosis to ecological remodeling: A new breakthrough in microbial treatment of inflammatory bowel disease.iScience · 2026Review
- Genetically engineered Escherichia coli Nissle 1917 enabling on-site melanin synthesis attenuates radiation enteritis through ferroptosis inhibition and gut microbiota modulation.Redox biology · 2026Article
- Efficacy of Second-Line Advanced Therapy in Patients with Crohn's Disease After Failure of a First Anti-TNF: A Descriptive Analysis.Journal of clinical medicine · 2026Article
- Oral administration of probiotic colony-like micro-nano system for immunoregulation of rheumatoid arthritis.Acta pharmaceutica Sinica. B · 2026Article
- Polydopamine Nanodots Ameliorate Inflammatory Bowel Disease by Restoring Redox Homeostasis and Intestinal Microenvironment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Microbial Modulation of the Gut-Liver Axis in Autoimmune Liver Diseases.Seminars in liver disease · 2025Review
- Colon-Targeted Natural Polysaccharide-Berberine Armored Hydrogel for the Treatment of Colitis.Advanced healthcare materials · 2025Article
- Qingjie Fuzheng Granule prevents colitis-associated colorectal cancer by inhibiting abnormal activation of NOD2/NF-Chinese herbal medicines · 2025Article
- A CRISPR-Cas9 system protecting E. coli against acquisition of antibiotic resistance genes.Scientific reports · 2025Article
- Diabetes as an independent risk factor for severe inflammatory bowel disease: evidence from an inflammation-metabolism-liver coupling framework.Frontiers in endocrinology · 2025Article
- Fabrication of Single-Bacterium Microgel with Gas-Shearing Strategy for Precision Probiotic Delivery in IBD Therapy.Research (Washington, D.C.) · 2025Article
- Comparative efficacy and safety of mesalazine-based regimens with traditional Chinese medicines in mild-to-moderate ulcerative colitis.Frontiers in pharmacology · 2025Article
- Recent advances in bacteria-based platforms for inflammatory bowel diseases treatment.Exploration (Beijing, China) · 2024Review
- Electrospun Nanofibers with Pomegranate Peel Extract as a New Concept for Treating Oral Infections.Materials (Basel, Switzerland) · 2024Article
- Article
- Effect of synbiotic supplementation on obesity and gut microbiota in obese adults: a double-blind randomized controlled trial.Frontiers in nutrition · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD) is a recurring chronic inflammatory disease. Current treatment strategies are aimed at alleviating clinical symptoms and are associated with gastrointestinal or systemic adverse effects. New delivery strategies are needed for the treatment of IBD. Bacteria are promising biocarriers, which can produce drugs in situ and sense the gut in real time. Herein, we focus on recent studies of engineered bacteria used for IBD treatment and introduce the application of engineered bacteria in the diagnosis. On this basis, the current dilemmas and future developments of bacterial delivery systems are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.